Global Acquired (Autoimmune) Hemolytic Anemia Market, Types (Warm Autoimmune Induced Hemolytic Anemia, Cold Agglutinin Disease (CAD) and Others), Treatment (Medication, Blood Transfusion, Surgery, Splenectomy, Others), Diagnosis (Blood Tests, Coombs Test, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Hemolytic anemia is a type of anemia that occurs when your red blood cells break down or die quicker than your body can replace them with new ones. Hemolytic anemia can be caused by inheriting anemia-causing genetic disorders, infections, or specific drugs. Hemolytic anemia treatment varies based on the origin of the sickness. Blood transfusions, corticosteroid medications, and Rituximab are all possible treatments. Surgery to remove the spleen is recommended in more severe cases. Warm antibody hemolytic anemia and cold antibody hemolytic anemia are two types of acquired (autoimmune) hemolytic anemia. Autoantibodies attach to red blood cells in warm antibody hemolytic anemia and destroy them at a temperature higher than body temperature; in cold antibody hemolytic anemia, self-generated antibodies kill red blood cells at a temperature lower than body temperature.
Data Bridge Market Research analyses that the acquired (autoimmune) hemolytic anemia market was valued at USD 676.75 million in 2021 and is expected to reach USD 992.28 million by 2029, registering a CAGR of 4.90% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Warm Autoimmune Induced Hemolytic Anemia, Cold Agglutinin Disease (CAD) and Others), Treatment (Medication, Blood Transfusion, Surgery, Splenectomy, Others), Diagnosis (Blood Tests, Coombs Test, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Fresenius SE & Co. KGaA (Germany), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Lupin (India), ViforPharma Ltd. (Switzerland), AMAG Pharmaceuticals (U.S.), Akebia Therapeutics, INC. (U.S.), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India), Zydus Cadila (India), Hikma Pharmaceuticals PLC (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Non-genetic acquired (autoimmune) hemolytic anemia arises when the body's own immune system eliminates healthy tissues in response to invading organisms such as lymphocytes and antibodies. The treatment focuses on three main goals: preventing RBC destruction, raising RBC count, and treating the underlying ailment. Major treatment options include blood transfusions, medicines, plasmapheresis, and procedures. To treat acquired (autoimmune) hemolytic anemia, medicines such as prednisone, rituximab, hydroxyurea, and cyclosporine are commonly used.
Acquired (Autoimmune) Hemolytic Anemia Market Dynamics
Drivers
- Increasing prevalence of iron-deficiency anemia
The rising prevalence of iron-deficiency anemia is estimated to influence the market's growth rate. Along with this, the growing incidences of autoimmune diseases such as lupus, rheumatoid arthritis, Sjogren's syndrome, thyroid disease, Hashimoto's disease and ulcerative colitis will influence the market dynamics during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of acquired (autoimmune) hemolytic anemia market is the rising healthcare expenditure, which helps improve its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, which will further influence the market dynamics.
- Increasing number of geriatric population
The increasing number of geriatric population is estimated to enhance the market's growth rate. According to the World Ageing 2020 estimate, there will be 727 million people aged 65 and up in the year 2020. In 2050, this population is expected to increase to 1.5 billion. The proportion of the geriatric population is estimated to rise. The elderly population is more prone to acquired (autoimmune) hemolytic anemia, further enhancing the market's growth rate. Acquired (autoimmune) hemolytic anemia can affect people of all ages and genders, though it most commonly occurs in females over the age of 40.
Furthermore, a surging number of government initiatives to spread awareness and sedentary lifestyle will result in the expansion of acquired (autoimmune) hemolytic anemia market. Along with this, rising level of disposable income and increase in the risk of haemodilution will enhance the market's growth rate.
Opportunities
- Rise in R&D activities
The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the acquired (autoimmune) hemolytic anemia market growth.
Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the acquired (autoimmune) hemolytic anemia market growth.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of the acquired (autoimmune) hemolytic anemia market during 2022-2029. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the acquired (autoimmune) hemolytic anemia market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the market's growth rate during the forecast period of 2022-2029.
This acquired (autoimmune) hemolytic anemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acquired (autoimmune) hemolytic anemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Autoimmune hemolytic anemia is rare, affecting approximately 1 to 2 of every 100,000 people yearly.
The acquired (autoimmune) hemolytic anemia market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence rates are some data variables available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Acquired (Autoimmune) Hemolytic Anemia Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for various reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of acquired (autoimmune) hemolytic anemia in recent months.
Recent Development
- In February 2022, The U.S. Food and Drug Administration (FDA) announced the approval of Enjaymo (sutimlimab-jome). It decreases red blood cell transfusion requirement due to hemolysis in adults with cold agglutinin disease (CAD). Enjaymo is the first as well as only approved treatment for people with CAD and functions by inhibiting the destruction of red blood cells (hemolysis).
Global Acquired (Autoimmune) Hemolytic Anemia Market Scope
The acquired (autoimmune) hemolytic anemia market is segmented on the basis of types, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Warm Autoimmune Induced Hemolytic Anemia
- Cold Agglutinin Disease (CAD)
- Others
Treatment
- Medication
- Corticosteroids
- Immunosuppressive agents
- Others
- Blood Transfusion
- Surgery
- Splenectomy
- Others
Diagnosis
- Blood Tests
- Coombs Test
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Acquired (Autoimmune) Hemolytic Anemia Market Regional Analysis/Insights
The acquired (autoimmune) hemolytic anemia market is analyzed and market size insights and trends are provided by country, types, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the acquired (autoimmune) hemolytic anemia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America and Europe dominate the acquired (autoimmune) hemolytic anemia market because of the well-established healthcare infrastructure in this region. Additionally, the growing focus of major key players on novel technology will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to the growing number of patient populations and the large number of generic manufacturers in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Acquired (Autoimmune) Hemolytic Anemia Market Share Analysis
The acquired (autoimmune) hemolytic anemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acquired (autoimmune) hemolytic anemia market.
Some of the major players operating in the acquired (autoimmune) hemolytic anemia market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- AbbVie Inc. (U.S.)
- Fresenius SE & Co. KGaA (Germany)
- Lupin (India)
- ViforPharma Ltd. (Switzerland)
- AMAG Pharmaceuticals (U.S.)
- Akebia Therapeutics, INC. (U.S.)
- CHO-A Pharmaceutical CO., LTD. (South Korea)
- Orion Corporation (Finland)
- Pharmacosmos A/S (Denmark)
- Shield Therapeutics (U.K.)
- Advanz Pharmaceutical (U.K.)
- Alkem Labs (India)
- Zydus Cadila (India)
- Hikma Pharmaceuticals PLC (U.K.)
SKU-